Evidence map›Paper›PMID 38064639›Full record

ArticleJournal of the American Chemical Society2023

Desymmetrization and Parallel Kinetic Resolution of 1-Ethynylcyclobutanols via Asymmetric Cooperative Gold Catalysis.

Ke Zhao, Ziguang Yang, Jielin Yang, Xinyi Li, Carlos D Quintanilla, Liming Zhang

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ke ZhaoDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California 93117, United States.ORCID 0000-0003-2301-490X
Ziguang YangDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California 93117, United States.
Jielin YangDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California 93117, United States.
Xinyi LiDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California 93117, United States.
Carlos D QuintanillaDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California 93117, United States.
Liming ZhangDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, California 93117, United States.ORCID 0000-0002-5306-1515
University of California, Santa Barbara · US

Funding

Research Supplements to Promote Diversity in Health-Related ResearchR35GM139640 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI Liming Zhang · 2021 to 2026
$2.5M
NIGMS NIH HHS R35 GM139640
6 · The paper itself

Abstract

Enantioselective gold catalysis remains a challenging area of research. By harnessing gold-ligand cooperation in the presence of a chiral bifunctional phosphine ligand featuring a novel 3'-phosphine oxide moiety, highly enantioselective desymmetrization of 1-ethynylcyclobutanols is achieved, permitting access to chiral α-methylenecyclopentanones featuring a diverse array of chiral quaternary and tertiary centers. This cooperative gold catalysis also enables parallel kinetic resolution in gold catalysis, delivering cyclopentanone regioisomers with excellent enantiomeric excesses. DFT calculations of the transition states support the distinct mechanism of asymmetric induction via controlling the conformation of the bound substrate and hence dictating the ring bond undergoing migration.

Identifiers

PMID38064639
PMCPMC11572530
OpenAlexW4389473658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.